Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval.
Accumulated evidence indicates that LDL apheresis can induce remission of nephrotic syndrome refractory to standard drug therapy, supporting calls to expand insurance and regulatory approval beyond focal segmental glomerulosclerosis (FSGS) to a wider range of causative diseases.
Background
Persistent hyperlipidemia in nephrotic syndrome is nephrotoxic and contributes to progressive glomerular and tubulointerstitial injury, particularly in FSGS. LDL apheresis rapidly removes apolipoprotein-B-containing lipoproteins from the circulation and has been used as an adjunct to corticosteroids and calcineurin inhibitors in drug-resistant disease. In Japan, LDL apheresis has been covered by national health insurance for drug-resistant FSGS since 1992, but coverage limited to FSGS has restricted access for patients with other causes of refractory nephrotic syndrome.
Key findings
Reviews and case series report that LDL apheresis combined with drug therapy yields more rapid relief of nephrotic syndrome and favorable long-term outcomes, with reported remission rates of roughly 60 to 70 percent in steroid-resistant FSGS cohorts. Earlier initiation after onset and a more pronounced reduction in LDL have been associated with better prognosis, and benefit has also been described in post-transplant recurrent FSGS. Evidence for diseases other than FSGS, while less extensive, has continued to accumulate.
Clinical implications
The collected evidence supports considering LDL apheresis in patients with treatment-resistant nephrotic syndrome and high LDL, ideally before a heavy burden of glomerulosclerosis develops. The authors argue that the breadth of beneficial data justifies expanding insurance coverage and regulatory approval beyond FSGS. However, much of the supporting literature comes from small, heterogeneous studies at moderate-to-high risk of bias, so larger prospective trials remain needed to define efficacy precisely.
Category
Research
Source
Ther Apher Dial
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.